- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
June 1, 2022Chambers USA Recognizes Five Robins Kaplan Practice Groups And 17 Lawyers In 2022 Guide
-
June 1, 2022Seasoned Attorney Joins Firm’s Business Litigation Group
-
May 26, 2022Shira Shapiro Named Woman of Promise By The Pearl Society
-
June 3, 202219th Annual Advanced Insurance Law
-
June 9, 2022Building Your Brand: Perspectives and Insights from a Diverse Bar
-
June 10, 2022LGBTQ Legal Services: Transgender Name Change Clinic
-
May 24, 2022Briefly: Seeking Fees and Costs While on Appeal
-
May 19, 202211th Circ. Ban On Service Awards May Inhibit Class Actions
-
May 13, 2022Trademark Applications and the Murky Waters of Subject Matter Jurisdiction
-
June 2, 2022Sandberg Stepping Down as Meta COO After 14 Years
-
June 1, 2022Markets Revert to Recent Form as Pessimism Takes Hold
-
May 27, 2022Unexpectedly Strong Retail Sales Pull Markets Back from the Brink
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
ANDA Litigation Settlements
Spring 2016
| Case Name | Drug | Patent No(s). | Publicly Available Terms |
|---|---|---|---|
|
Depomed, Inc. v. Endo Pharms. Inc., 13-2467 (D.N.J.) |
Opana ER® (oxymorphone hydrochloride extended-release tablets) |
6,340,475 |
N/A |
|
In re: Certain Consolidated Zoledronic Acid Cases, 12-03967 (D.N.J.) |
Reclast® (zoledronic acid)
|
7,932,241
|
Novartis Pharms. Corp. and Actavis LLC agree to settle all claims that both parties have asserted against each other. |
|
Acorda Therapeutics Inc. v. Par Pharm. Inc., 15-0824 (D. Del.) |
Ampyra® (dalfampridine extended-release tablets) |
8,007,826
|
Par agrees not to market its ANDA product in the U.S. until 2027. But there are certain circumstances that would allow Park to market its ANDA product earlier, though they are confidential. |
|
Forest Labs. Inc. v. Apotex Corp., 13-1602 (D. Del.) |
Savella® (milnacipran hydrochloride tablets) |
6,602,911
|
Apotex is barred from selling any generic milnacipran hydrochloride product described in its ANDA before the three patents expire without first obtaining a license from Forest. Both parties also agreed to waive any right to an appeal and additionally agreed that all other claims against one another should be dismissed without prejudice. |
|
Apotex Inc. v. Lupin Ltd., 15-0599 (E.D. Tex.) |
Paxil® (paroxetine) |
7,229,640
|
N/A |
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.